Processing and release of insulin and insulin-like growth factor I by macro- and microvascular endothelial cells.
Insulin and insulin-like growth factor I (IGF-I) processing by macro- and microvascular endothelial cells was investigated. Specific binding of insulin and IGF-I on the capillary endothelial cells derived from rat fat pads was 4 +/- 0.5% (+/- SE) and 4.3 +/- 0.3%/mg protein, respectively, in contrast to bovine aortic endothelial cells, which bound 9.3 +/- 0.3% IGF-I/mg protein. Both binding and processing of insulin and IGF-I were time and temperature dependent in macro- and microvascular endothelial cells. After 30 min at 37 C, between 40-50% of the bound IGF-I and insulin were internalized in both capillary and aortic endothelial cells, whereas 20-25% insulin and 15-20% IGF-I internalization were observed at 15 C. Less than 20% internalization was observed for both insulin and IGF-I at 4 C. Cellular inhibitors of hormone processing, such as chloroquine and monensin, enhanced cell-associated insulin at 37 C on the bovine aortic endothelial cells from 4.7% to 10.4 +/- 1% and 9.9 +/- 2% mg protein, respectively, at 60 min. Similarly, chloroquine and monensin increased the amount of [125I]IGF-I associated with aortic endothelial cells from 4.3 +/- 0.2% to 5.5 +/- 0.3% and 6.2 +/- 0.7%/mg protein, respectively. Chloroquine and monensin increased [125I]insulin associated with rat capillary endothelial cells from a control of 2.9 +/- 0.1% to 4.0 +/- 0.2% and 3.8% +/- 0.37%, respectively. No effect of chloroquine and monensin was observed on [125I]IGF-I binding to rat capillary endothelial cells. Leupeptin, a lysosomal protease inhibitor, did not affect insulin or IGF-I binding in either cell type. The internalized insulin and IGF-I were both rapidly released, with 70-80% of both hormones being detected in the medium by 120 min. The released hormones were mostly intact (greater than 80-90%), as assessed by trichloroacetic acid precipitability, gel filtration, and immunoprecipitation. Both insulin and IGF-I induced corresponding down-regulation of their receptors, as shown by a 66 +/- 7% decrease in insulin binding in the capillary endothelial cells and a 72 +/- 1% and 58 +/- 1% decrease in IGF-I binding in the aortic and capillary endothelial cells, respectively. Thus, macro- and microvascular endothelial cells bind and process insulin and IGF-I by degradative and nondegradative pathways. The predominance of the nondegradative pathway for the processing of insulin and IGF-I and the modulation of their receptors by physiological hormone concentrations suggested that endothelial cells may regulate the access of insulin and IGF-I to their target cells.
D000818:Animals; D001011:Aorta / Q000166:cytology / Q000378:metabolism*; D002196:Capillaries / Q000166:cytology / Q000378:metabolism*; D002417:Cattle; D002738:Chloroquine / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D008297:Male; D008833:Microcirculation; D008854:Microscopy, Electron; D008985:Monensin / Q000494:pharmacology; D051381:Rats; D011972:Receptor, Insulin / Q000378:metabolism; D013002:Somatomedins / Q000378:metabolism*; D013696:Temperature; D013997:Time Factors
D007328:Insulin; D013002:Somatomedins; D002738:Chloroquine; D008985:Monensin; D011972:Receptor, Insulin